Rimidi is a health IT platform that enables virtual, personalized management of cardiometabolic diseases.
Rimidi has raised $5.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2023.
Rimidi's investors include Eli Lilly, Village Capital, VentureWell, The JumpFund, Cox Enterprises.
Rimidi is headquartered in Atlanta, United States.
Rimidi is a health IT platform that enables virtual, personalized management of cardiometabolic diseases.
Rimidi is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rimidi — Funding & Investors." VCBacked, January 12, 2023, https://www.vcbacked.co/company/rimidi. Accessed September 13, 2026.
VCBacked. (2023). Rimidi — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/rimidi
{{cite web |title=Rimidi — Funding & Investors |url=https://www.vcbacked.co/company/rimidi |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated